<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(mark one)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _______________ TO _____________
COMMISSION FILE NUMBER 0-20096
GLIATECH INC.
(Exact name of registrant as specified in its charter)
DELAWARE 34-1587242
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
23420 COMMERCE PARK ROAD
CLEVELAND, OHIO 44122
(Address of principal executive offices) (Zip Code)
(216) 831-3200
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES X NO
----- ----
The number of shares outstanding of the registrant's Common Stock, $0.01 par
value per share, as of August 7, 1998 was 9,913,070 shares.
<PAGE> 2
GLIATECH INC. AND SUBSIDIARIES
(A Development Stage Enterprise)
INDEX
<TABLE>
<CAPTION>
PART I. FINANCIAL INFORMATION PAGE
- ------- --------------------- ----
<S> <C> <C>
Item 1 Financial Statements:
Consolidated Balance Sheets - 1
December 31, 1997 and June 30, 1998 (unaudited)
Consolidated Statements of Operations -
for the three months and six months ended June 30, 1997 and 1998
and for the period from inception of operations
(August 31, 1988) through June 30, 1998 (unaudited) 2
Consolidated Statements of Cash Flows for the six months ended June
30, 1997 and 1998 and for the period from inception of operations
(August 31, 1988) through June 30, 1998 (unaudited) 3
Notes to Consolidated Financial Statements 4
Item 2 Management's Discussion and Analysis of Financial Condition 5-9
and Results of Operations
Item 3 Quantitative and Qualitative Disclosures About Market Risk 10
PART II. OTHER INFORMATION
Item 2 Changes in Securities and Use of Proceeds 11
Item 4 Submission of Matters to a Vote of Security-Holders 12
Item 6 Exhibits and Reports on Form 8-K 13
</TABLE>
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
GLIATECH INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE ENTERPRISE)
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31, JUNE 30,
1997 1998
---------------- ----------------
(unaudited)
ASSETS
Current assets:
<S> <C> <C>
Cash and cash equivalents $5,601,398 $24,893,363
Short-term investments 5,940,476 1,005,346
Accounts receivable 544,051 987,517
Government grants receivable 207,080 293,457
Inventories 164,078 678,683
Prepaid expenses and other 278,714 193,011
---------------- ----------------
Total current assets 12,735,797 28,051,377
Property and equipment, net 1,277,519 1,374,388
Other assets, net 792,072 811,271
---------------- ----------------
TOTAL ASSETS $14,805,388 $30,237,036
================ ================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and other accrued expenses 1,686,356 2,673,615
Accrued compensation 179,018 98,557
Accrued clinical trial costs 690,885 947,628
Deferred research contract revenue 809,359 72,362
---------------- ----------------
Total current liabilities 3,365,618 3,792,162
Stockholders' equity:
Common stock 74,013 93,498
Additional paid-in capital 53,379,810 72,801,619
Deficit accumulated during the development stage (42,014,053) (46,450,243)
---------------- ----------------
Total stockholders' equity 11,439,770 26,444,874
---------------- ----------------
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY $14,805,388 $30,237,036
================ ================
</TABLE>
1
<PAGE> 4
GLIATECH INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE ENTERPRISE)
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
<TABLE>
<CAPTION>
PERIOD FROM
INCEPTION OF
OPERATIONS
(AUGUST 31, 1988)
THREE MONTHS ENDED SIX MONTHS ENDED THROUGH
JUNE 30 JUNE 30 JUNE 30
------------------------------ --------------------------------- ------------------
1997 1998 1997 1998 1998
------------ --------------- --------------- --------------- ------------------
<S> <C> <C> <C> <C> <C>
REVENUES
Product sales 337,324 1,150,870 681,980 1,662,370 4,368,315
Research contracts and licensing fees 738,500 738,500 1,477,000 1,477,000 10,420,219
Government grants 100,682 259,923 151,022 410,257 1,910,972
---------- ---------- ---------- ---------- -----------
Total revenues 1,176,506 2,149,293 2,310,002 3,549,627 16,699,506
OPERATING COSTS AND EXPENSES
Cost of products sold 138,963 297,832 263,704 464,666 1,601,061
Research and development 1,971,480 2,379,389 3,826,409 4,632,403 38,630,722
Selling, general and administrative 1,120,426 1,750,347 2,190,331 2,983,220 21,562,850
Depreciation and amortization 68,386 98,490 133,299 185,338 1,922,873
---------- ---------- ---------- ---------- -----------
Total operating cost and expenses 3,299,255 4,526,058 6,413,743 8,265,627 63,717,506
---------- ---------- ---------- ---------- -----------
Loss from operations (2,122,749) (2,376,765) (4,103,741) (4,716,000) (47,018,000)
Interest Income, net 217,179 133,001 453,991 279,809 3,531,778
Settlement of Claim 0 0 0 0 (2,025,000)
========== ========== ========== ========== ===========
NET LOSS (1,905,570) (2,243,764) (3,649,750) (4,436,191) (45,511,222)
========== ========== ========== ========== ===========
Basic and diluted net loss per common share (0.26) (0.28) (0.50) (0.57)
========== ========== ========== ==========
Shares used for purposes of computing
basic and diluted net loss per
common share 7,346,836 8,044,761 7,341,461 7,768,980
========== ========== ========== ==========
</TABLE>
2
<PAGE> 5
GLIATECH INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE ENTERPRISE)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
PERIOD FROM
INCEPTION OF
OPERATIONS
(AUGUST 31, 1988)
THROUGH
SIX MONTHS ENDED JUNE 30,
-------------------------------- -----------------
1997 1998 1998
----------- ----------- ------------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net loss ($3,649,750) ($4,436,191) ($45,511,222)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 133,299 185,338 1,922,873
Patent Cost Write-off 100,000 49,998 557,740
Loss on disposal of equipment - - 102,000
Compensation from issuance of stock and stock options - - 286,609
Settlement of claim - - 2,025,000
Changes in operating assets and liabilities:
Accounts receivable (116,473) (443,466) (987,517)
Inventory 53,738 (514,605) (678,683)
Government grants receivable and other assets (129,872) (674) (496,467)
Accounts payable 302,552 987,262 2,666,947
Deferred contract research revenue (738,500) (737,000) 72,359
Other liabilities (23,503) 176,282 1,489,616
----------- ----------- ------------
Net cash used in operating activities (4,068,509) (4,733,056) (38,550,745)
INVESTING ACTIVITIES
Sale (purchase) of investments, net 2,835,911 4,935,130 (1,005,346)
Payment for patent rights and trademarks (96,903) (91,347) (1,463,904)
Payment of organization costs - - (139,779)
Purchase of property and equipment (196,992) (260,057) (2,659,620)
----------- ----------- ------------
Net cash provided by (used in) investing activities 2,542,016 4,583,726 (5,268,649)
FINANCING ACTIVITIES
Payment of demand note from bank - - -
Principal payments on capital lease obligations - - (565,601)
Proceeds from sale and leaseback - - 75,131
Proceeds from issuance of Preferred Stock, net - - 28,976,554
Proceeds from issuance of Common Stock, net - 19,261,166 39,078,446
Proceeds from exercise of stock options 174,625 180,128 648,225
Proceeds from exercise of warrants - - 500,001
----------- ----------- ------------
Net cash (used in) provided by financing activities 174,625 19,441,294 68,712,756
----------- ----------- ------------
Increase (decrease) in cash and cash equivalents (1,351,868) 19,291,964 24,893,362
Cash and cash equivalents at beginning of period 9,120,547 5,601,398 -
----------- ----------- ------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $7,768,679 $24,893,362 $24,893,362
=========== =========== ============
</TABLE>
See notes to consolidated financial statements
3
<PAGE> 6
GLIATECH INC. AND SUBSIDIARIES
(A Development Stage Enterprise)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
Note 1. Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Operating results for the six-month period ended 1998 are not
necessarily indicative of the results that may be expected for the year ending
December 31, 1998. These financial statements should be read in conjunction with
the consolidated financial statements and footnotes thereto included in the
Annual Report on Form 10-K of Gliatech Inc. for the fiscal year ended December
31, 1997 filed with the Securities and Exchange Commission.
The Company has been in the development stage, which requires the Company to
report cumulative revenues and expenses, cumulative changes in financial
position and changes in stockholders' equity since inception. In May 1998,
ADCON(R)-L was approved by the United States Food and Drug Administration for
sale in the United States. The Company anticipates that in the third quarter of
1998 sales in the United States will significantly increase and therefore, the
Company will no longer be a development stage company.
Note 2. Basic and Diluted Net Loss per Common share
Basic and diluted net loss per common share, for the three and six month periods
ended June 30, 1998 and 1997, is based on the weighted average number of common
shares outstanding.
Note 3. Public Offering of Common Stock
In June 1998, the Company sold 1,725,000 shares of Common Stock in a public
offering. The Company received proceeds of approximately $19.5 million from
such offering.
4
<PAGE> 7
ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Since commencing operations in 1988, the Company has been a development stage
company. The Company is engaged in research, development and commercialization
of the ADCON family of products, which are proprietary, resorbable, carbohydrate
polymer medical devices designed to inhibit surgical scarring and adhesions.
Based on European pivotal clinical studies and other compliance efforts and
submission of data, the Company obtained regulatory clearance to affix CE
Marking on ADCON(R)-L and ADCON(R)-T/N in August 1995 and January 1996,
respectively, thereby allowing ADCON(R)-L and ADCON(R)-T/N to be marketed in the
19 European countries which recognize CE marking for lumbar disc surgery and
tendon and peripheral nerve surgeries respectively. ADCON(R)-L and ADCON(R)-T/N
are currently being marketed in 29 countries outside the U.S. through
independent medical device distributors. On May 27, 1998, the Company received
approval to market ADCON(R)-L in the U.S. from the U.S. Food and Drug
Administration ("FDA"). In addition, the Company signed a development and
exclusive license agreement in December 1996 with Chugai for the sale of
ADCON(R)-L and ADCON(R)-T/N in Japan. The Company is also pursuing the
development of small molecule drug candidates for the treatment of several
nervous system disorders, including Attention Deficit Hyperactive Disorder
("ADHD"), sleep disorders, anxiety and Alzheimer's disease ("AD"). In October
1994, the Company entered into a strategic alliance with Janssen Pharmaceutica,
N.V. of Belgium ("Janssen") to collaborate on the discovery and development of
therapeutic models to treat AD. In September 1995, the scope of the alliance was
expanded and the current arrangement extends through October 1998.
Since inception, the Company's revenues have been primarily from contract
research payments relating to its strategic alliance with Janssen. The Company
has also received revenues from product sales of ADCON(R)-L and ADCON(R)-T/N
outside the U.S. and revenues from product sales within the U.S. beginning in
mid-June 1998. The Company also receives revenues from various government grants
awarded to the Company. The Company anticipates that a significant portion of
revenue from product sales will be derived from its ADCON(R) family of products,
primarily ADCON(R)-L. In June 1998, the Company received proceeds of
approximately $19.5 million in connection with the completion of a public
offering of 1,725,000 shares of Common Stock. The Company currently is a
development stage company, which requires the Company to report cumulative
revenues and expenses, cumulative changes in financial position and changes in
stockholders equity since inception. In May 1998, ADCON(R)-L was approved by the
FDA for sale in the U.S. As a result the Company anticipates that in the third
quarter of 1998 sales in the U.S. will significantly increase and therefore, the
Company will no longer be a development stage company.
5
<PAGE> 8
The Company has had net operating losses since its inception and expects such
losses to continue unless and until such time as revenues are sufficient to fund
its current operations. The Company has accumulated a deficit of $46.5 million
for the period from inception of operations (August 31, 1988) through June 30,
1998. The Company expects to continue to incur a loss over at least the next
several years and the amount of future net losses and time required by the
Company to reach profitability are uncertain.
RESULTS OF OPERATIONS
For the three and six months periods ended June 30, 1998 and 1997.
REVENUES
Total revenues increased 82.7% to $2.1 million in the second quarter of 1998
from $1.2 million in the second quarter of 1997 and 53.7% to $3.6 million in the
first six months of 1998 from $2.3 million in the first six months of 1997. The
increase in total revenues is primarily the result of an increase in product
sales which more than tripled to $1.2 million in the second quarter of 1998 from
$337,324 in the second quarter of 1997. This increase in product sales resulted
primarily from the commercialization in the U.S. of the Company's first product,
ADCON(R)-L. ADCON(R)-L was approved for marketing in the U.S. by the FDA in May
1998. The Company commenced sales of ADCON(R)-L in the U.S. in mid-June 1998.
The Company's government-funded grant revenues increased 158.2% to $259,923 in
the second quarter of 1998 from $100,682 in the second quarter of 1997 and
increased 171.1% to $410,257 in the first six month of 1998 compared to $151,022
in the first six months of 1997. This increase was a result of a higher level of
government funded revenues primarily due to the award in February 1997 of a
Phase II Small Business Innovation Research ("SBIR") Program two year grant from
the National Institute of Neurological Disorders and Stroke ("NINDS") for
research to evaluate the histamine H3 receptor antagonists. The increase is also
the result of an award in the second quarter of 1998 of two $97,500 Phase I SBIR
Program grants from NIH for additional drug development research.
OPERATING COSTS AND EXPENSES
Total operating expenses increased by 37.2% to $4.5 million in the second
quarter of 1998, compared to $3.3 million in the second quarter of 1997, and
increased 28.9% to $8.3 million in the first six months of 1998 compared to $6.4
million in the first six months of 1997. Cost of products sold increased 114.3%
to $297,832 in the second quarter of 1998 compared to $138,963 in the second
quarter of 1997, but decreased, as a percentage of product sales, in the second
quarter of 1998 to 25.9% from 41.2% in the second quarter of 1997. Cost of
products sold increased 76.2% in the
6
<PAGE> 9
first six months of 1998 to $464,666 compared to $263,704 in the first six month
of 1997 but decreased as a percentage of products sales in the first six months
of 1998 to 28% from 38.7% in the first six months of 1997. The percentage
decrease in both the second quarter and in the first six months of 1998 were
primarily due to: (i) increased production volumes and (ii) the favorable impact
of the unit sales prices of ADCON(R)-L in the United States
Research and development expenses increased by 20.7 % to $2.4 million in the
second quarter of 1998 from $2.0 million in the second quarter of 1997 and
increased 21.1% to $4.6 million in the first six months of 1998 from $3.8
million in the first six months of 1997. This increase was primarily due to: (i)
increased research contract expenses and purchases of materials for animal
toxicology and other preclinical studies for the lead compound which is being
developed by the Company for its cognition modulation program; and (ii)
increased staffing and clinical research costs associated with the completed
pilot clinical trial of ADCON(R)-P.
Selling, general and administrative expenses increased 56.2% to $1.8 million in
the second quarter of 1998 compared to $1.1 million in the second quarter of
1997 and increased 36.2% to $3.0 million in the first six months of 1998 from
$2.2 million in the first six months of 1997. This increase was primarily due to
an increase in the sales and marketing expenses resulting from the Company's
preparation for the sale of ADCON(R)-L in the U.S.
Depreciation and amortization expense increased 44% to $98,490 in the second
quarter of 1998 compared to $68,386 in the second quarter of 1997 and increased
39% to $185,338 in the first six months of 1998 compared to $133,299 in 1997.
The increase was primarily due to increased amortization resulting from
leasehold improvements made in 1997.
INTEREST INCOME
Net interest income decreased to $133,001 in the second quarter of 1998 from
$217,179 in the second quarter of 1997 and decreased to $279,809 in the first
six months in 1998 from $453,991 in the first six months in 1997. This decrease
in both periods was due to lower cash, cash equivalents and short-term
investment balances during the first and second quarters of 1998 as compared to
the first and second quarters of 1997.
NET LOSS
Gliatech's net loss increased 17.7% to $2.2 million in the second quarter of
1998, compared to $1.9 million in the second quarter of 1997 and increased 21.5%
to $4.4 million for the first six months of 1998 from $3.7 million in the first
six months of 1997. The increase in net loss is a result of increased total
expenses, which were slightly offset by increased revenues as discussed above.
The basic and diluted net loss per common share was $0.28 in the second quarter
of 1998, compared to $0.26 in the second quarter of 1997 and $0.57 in the first
six months of 1998, compared to $0.50 in the first six months of 1997.
7
<PAGE> 10
LIQUIDITY AND CAPITAL RESOURCES
Since inception, the Company has financed its operations primarily through the
private placement and public offering of its equity securities, research
contract licensing fees, and, to a lesser extent, through federally sponsored
research grants. In June 1998, the Company raised additional funds through a
public offering of 1,725,000 shares of its Common Stock at a price of $12.00 per
share, including the exercise of the over-allotment option of 225,000 shares.
The shares were sold through a group of underwriters for whom Cowen & Company,
Furman Selz LLC and Vector Securities International, Inc. acted as managing
underwriters. Since its inception, the Company has received $68.7 million in net
proceeds from equity financings. In addition, from its inception through June
30, 1998, the Company has recognized revenue of $10.4 million from its research
collaboration agreement with Janssen, $4.4 million from product sales and $1.9
million from several federally sponsored research grants. The Company also has
established a $1.5 million line of credit with a bank. As of June 30, 1998, the
Company had no borrowings against the line of credit.
In order to preserve principal and maintain liquidity, the Company's funds are
invested in commercial paper and other short-term investments. As of June 30,
1998 and December 31, 1997, the Company's cash and cash equivalents and
short-term investments totaled $25.9 million and $11.5 million, respectively.
The Company expects that its existing capital resources and interest earned
thereon will enable the Company to maintain its current and planned operations
at least through mid-2000.
In February 1997, the Company was awarded a Phase II SBIR Program grant, from
NINDS for research evaluating histamine H3 receptor antagonists to treat ADHD.
The grant has a two-year term and may provide as much as $750,000 in funding. If
the Company is successful in other Phase I research, additional Phase II awards
may be sought for funding to aid in further development of pharmaceutical
compounds, however, there is no assurance that such Phase I research will be
successful or that additional funding will be obtained. In addition, in the
second quarter of 1998, the Company was awarded two Phase I SBIR grants for up
to $97,500 each form National Heart, Lung and Blood Institute and National
Institute of Mental Health both divisions of the National Institute of Health.
The Company does not expect to generate a positive cash flow from operations for
several years due to the substantial cost for commercialization of its ADCON(R)
family of products, additional research and development cost for ADCON(R)-A
(abdominal surgery), ADCON(R)-I (implant surgery) and ADCON(R)-C (cardiac
surgery) and for costs related to its Cognition Modulation and AD programs,
preclinical testing, clinical trials and operating expenses associated with
supporting such activities.
The Company may raise additional funds through additional equity or debt
financing, government grants, future corporate alliances, collaboration
relationships or otherwise. The Company may engage in these capital raising
activities even if it does not have an immediate need for additional
8
<PAGE> 11
capital at that time. There can be no assurance that any such additional funding
will be available to the Company or, if available, that it will be on acceptable
terms. If additional funds are raised by issuing equity securities, further
dilution to existing stockholders may result. If the Company seeks to obtain
funds through arrangements with collaborative partners or others, such partners
may require the Company to relinquish rights to certain of its technologies,
product candidates or products that the Company would otherwise seek to develop
or commercialize itself.
YEAR 2000. The Company has conducted a review of its information systems to
identify any issues that could be affected by the year 2000. The Company
believes that its network information systems, including Network Operating
System (NOS) software and Enterprise Resource Planning (ERP) software have been
thoroughly tested as Year 2000 compliant, and should be able to process year
and data information beyond the year 1999, however, there can be no assurance
that the Company's information systems will prove to be year 2000 compliant.
Further, the Company has yet to determine the extent to which year 2000 issues
will affect its independent distributors, independent manufacturers' agents, or
its contract manufacturer in tracking sales and orders of shipments of the
Company's devices or drugs, as the case may be. Any interruption in the
manufacturing or marketing of the Company's products could have a material
adverse effect on the Company's business, prospects, financial condition or
results of operations.
FORWARD-LOOKING STATEMENTS. Certain statements in this Quarterly Report on Form
10-Q constitute "forward-looking statements." When used in this Report, the
words "believes," "anticipates," "expects," "intends" and other predictive,
interpretive and similar expressions are intended to identify such
forward-looking statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual results
of the Company to be different from expectations expressed or implied by such
forward-looking statements. Such factors included, but are not limited to,
commercial uncertainty of market acceptance of the Company's ADCON(R) family of
products, delays in product development of other ADCON(R) products, including
the timing and content of decisions made the FDA, uncertainty due to the early
stage of development for the therapeutic programs, the possible need for
additional funding, the ability of the Company to establish and maintain
collaborative arrangements with others, the potential market size for ADCON(R)
products, the ability to renew research collaborations, the productivity of
distributors of the ADCON(R) products, shortages of supply of ADCON(R) products
from the Company's sole manufacturer, the lack of supply of raw materials for
the Company's products, uncertainty of future profitability, uncertainties
related the to the Company's proprietary rights in its products, the loss of key
management, and personnel and technological change. These statements are based
on certain assumptions and analysis made by the Company in light of its
experience and its perception of historical trends, current conditions, expected
future developments and other factors it believes are appropriate in the
circumstances. Such statements are subject to a number of other assumptions,
risks, uncertainties, general economic and business conditions, and the business
opportunities (or lack thereof) that may be presented to and pursued by the
Company. Prospective investors are cautioned that any such statements are not
guarantees of future performance and that actual results or developments may
differ materially from those projected in the forward-looking statements.
9
<PAGE> 12
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURE
ABOUT MARKET RISK
Not applicable
10
<PAGE> 13
PART II
OTHER INFORMATION
ITEM 2: CHANGES IN SECURITIES AND USE OF PROCEEDS
The Company registered 2,300,000 shares of Common Stock in connection with its
initial public offering on a Registration Statement on Form S-1, which went
effective on October 18, 1995. The data below reflects the use of proceeds from
such offering to the date of this Quarterly Report on Form 10-Q. All such
proceeds were directly or indirectly paid to others pursuant to Rule
701(f)(4)(vii):
Construction 0
Machinery and Equipment 0
Real Estate 0
Acquisition 0
Repayment of Debt 0
Working Capital 532,000
Temporary Investments (specify)
Commercial paper 4,453,000
Corporate Bonds 2,010,000
Other Short-Term Investments 175,000
Other:
Clinical Trials 2,503,000
Research and Development 6,618,000
Sales and Marketing 3,283,000
General Corporate Purposes 73,000
11
<PAGE> 14
PART II
OTHER INFORMATION
ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS
On May 20, 1998, at the Annual Meeting of Stockholders of Gliatech Inc., the
stockholders took the following actions:
(1) Elected as Directors all nominees designated in the Proxy Statement
dated April 13, 1998; and
(2) Approved the appointment of the independent certified public accountants
of the Company for the current fiscal year.
The Directors were elected pursuant to the following vote:
BROKER
NOMINEE FOR WITHHELD ABSTAIN NON-VOTE
Thomas O. Oesterling 6,034,644 68,506 ---- ----
Robert P. Pinkas 6,035,678 67,472 ---- ----
In addition, the following Directors' term of office continued after the
meeting: Robert P. Pinkas, Thomas O. Oesterling, Ph.D., Allen H. Ford, Theodore
E. Haigler, Jr., Ronald D. Henriksen, Irving S. Shapiro, and John L. Ufheil.
The approval of appointment of Ernst & Young LLP as independent certified public
accountants to the Company for its current fiscal year was approved by the
following vote:
BROKER
FOR AGAINST WITHHELD ABSTAIN NON-VOTE
6,082,835 17,470 0 2,845 ----
12
<PAGE> 15
ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
27.1 Financial data schedule
(b) Reports on Form 8-K
The Company filed a Current Report on Form 8-K on May 28, 1998.
13
<PAGE> 16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersgned thereunto duly authorized.
GLIATECH INC.
Date: August 14, 1998
By: /s/ Rodney E. Dausch
-------------------------
Rodney E. Dausch
Vice President, Chief Financial Officer
and Secretary
(Duly Authorized Officer and Principal
Financial and Accounting Officer)
<PAGE> 17
EXHIBIT INDEX
Exhibit No. Description of Exhibit Page Number
- ----------- ---------------------- -----------
27.1 Financial Data Schedule 16
15
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GLIATECH
INC'S QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 1998 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> JUN-30-1998
<CASH> 24,893
<SECURITIES> 1,005
<RECEIVABLES> 1,056
<ALLOWANCES> 69
<INVENTORY> 679
<CURRENT-ASSETS> 28,051
<PP&E> 3,010
<DEPRECIATION> 1,636
<TOTAL-ASSETS> 30,237
<CURRENT-LIABILITIES> 3,792
<BONDS> 0
0
0
<COMMON> 93
<OTHER-SE> 26,445
<TOTAL-LIABILITY-AND-EQUITY> 30,237
<SALES> 1,662
<TOTAL-REVENUES> 3,550
<CGS> 465
<TOTAL-COSTS> 465
<OTHER-EXPENSES> 7,801
<LOSS-PROVISION> 27
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (4,436)
<INCOME-TAX> 0
<INCOME-CONTINUING> (4,436)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (4,436)
<EPS-PRIMARY> (.57)
<EPS-DILUTED> (.57)
</TABLE>
